KRAS and neoplasm: In terms of the above-mentioned clinical characteristics (age, tumor location, intestinal wall thickness, tumor TNM stage, and histological type), there is no significant difference between the KRAS gene wild-type group and the mutant group in the training set and the validation set, as shown in Table 1.